GlassScriptPhysician profile
Bridget M Kilbride
NPI 1225522733
$13,659.56
in general payments reported to CMS, 2019-2025
26 companies · $4,636 in 2025
The $4,636 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $882 · 2022: $1,567 · 2023: $2,369 · 2024: $4,205 · 2025: $4,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,324 · Education: $1,087 · Consulting Fee: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,323.50 |
| Education | $1,086.61 |
| Consulting Fee | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,119.15 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,428.03 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $1,131.63 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $1,013.11 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $968.88 | 2021-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $929.08 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $917.97 | 2021-2025 | |
| Amgen INC. | $804.83 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $552.58 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $519.02 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $396.07 | 2023-2025 | Zoryve |
| Incyte Corporation | $348.55 | 2021-2025 | Opzelura |
| Organon LLC | $325.82 | 2025 | Vtama, Nexplanon |
| Leo Pharma INC. | $309.53 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $263.32 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $224.79 | 2021-2025 | Nemluvio, Aklief |
| Organogenesis INC. | $97.67 | 2021-2025 | Novachor, Puraply Wound Matrix |
| Sanofi-Aventis U.S. LLC | $64.95 | 2022 | |
| Mimedx Group, INC. | $51.57 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.58 | 2021 | |
| Dermavant Sciences, INC. | $31.42 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $28.98 | 2021 | |
| Dermira, INC. | $25.99 | 2021 | |
| Botanix Sb INC | $24.64 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $16.30 | 2023 | |
| Sandoz INC. | $16.10 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Kilbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.